MARKET

BNTC

BNTC

Benitec Biopharm
NASDAQ
12.00
+0.58
+5.08%
After Hours: 12.00 0 0.00% 16:10 04/13 EDT
OPEN
11.40
PREV CLOSE
11.42
HIGH
12.22
LOW
11.17
VOLUME
103.85K
TURNOVER
--
52 WEEK HIGH
17.15
52 WEEK LOW
9.85
MARKET CAP
412.25M
P/E (TTM)
-10.8303
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BNTC last week (0406-0410)?
Weekly Report · 19h ago
Weekly Report: what happened at BNTC last week (0330-0403)?
Weekly Report · 04/06 10:05
Weekly Report: what happened at BNTC last week (0323-0327)?
Weekly Report · 03/30 10:05
Weekly Report: what happened at BNTC last week (0316-0320)?
Weekly Report · 03/23 10:01
Weekly Report: what happened at BNTC last week (0309-0313)?
Weekly Report · 03/16 10:02
Benitec To Highlight Key Clinical Results Observed To Date For OPMD Patients Enrolled Into BB-301 Phase 1b/2a Clinical Treatment Study And Potential For BB-301 To Transform Treatment Landscape For Patients With OPMD At 2026 MDA Clinical and Scientific Conference
Benzinga · 03/10 11:09
Benitec Biopharma to host MDA conference industry forum breakfast on BB-301 OPMD trial results
Reuters · 03/10 11:03
Benitec Biopharma publishes corporate presentation on BB-301 durability in oculopharyngeal muscular dystrophy dysphagia###
Reuters · 03/09 23:52
More
About BNTC
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Webull offers Benitec Biopharma Inc stock information, including NASDAQ: BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.